Page 128 - Apollo Book complete

Clinical Apollo Consultants’
2019 Telemedicine CSR Academics Recognition Research
Excellence Homecare Achievements
Research

Apollo Hospitals Educational and diagnostics, drug delivery vehicles and cell free
Research Foundation (AHERF) therapeutics. AHERF has made a foray into diagnostics
and drug delivery system and is making efforts to
AHERF is a not for profit organisation recognised by develop exosome-based therapeutics.
the Department of Scientific and Industrial Research
(DSIR) and is focused on basic, translational and Biomarkers: Exosome biology was used to detect
serum EGFRvIII from the blood which stood as a
epidemiological research. AHERF comprises of the
diagnostic marker for detecting high grade gliomas.
Cell and Molecular Biology Research Centres
CMBRC is working on for establishment of detection
(CMBRC) situated at Chennai, Hyderabad and Delhi.
CMBRC enables basic and translational research biomarkers in diabetic nephropathy, renal transplant
projects in cutting edge areas such as liquid biopsy, rejection and head and neck cancers.
molecular diagnostics, pharmacogenetics and
Glioblastomas: The liquid biopsy testing for GBM was
exosomes. Further AHERF also spearheads a faculty
conceptualized in AHERF and proof of concept
development programme to spawn research pilots for achieved. This underwent further dual validation in
basic research projects. collaboration with a diagnostics partner. AHERF
developed and used exosome technology for the
Accreditation
studies. AHERF provided a platform for scientists in
the laboratory to work with clinicians at the hospital to
Association for the Accreditation of Human Research
establish an alternative method for diagnosis of high-
Protection Program (AAHRPP) Accreditation-
grade brain tumours using an exosome platform.
AHERF has been awarded full accreditation and
AHERF along with its partners, introduced liquid
honoured with the global 'gold seal' by AAHRPP. To
earn AAHRPP accreditation, AHERF provided tangible biopsies as part of its precision oncology program –
evidence of their commitment to scientifically and Apollo Hospitals unique approach for precise and
personalised diagnoses, treatment and monitoring of
ethically sound research and continuous improvement
cancer.
through policies, procedures, and practices. As the
'gold seal' AAHRPP accreditation assures that the Drug Delivery agents: CMBRC is in the initial process
Human Research Protection Program is focused first of working on exosomes as drug delivery agents and
and foremost on excellence. Five Ethics Committees further research to deploy exosomes as therapeutic
and 13 Apollo Hospitals sites fall under the purview of agents.
this accreditation.
AHERF is working on various research projects using
Projects exosome technology as a base platform. The projects
focus on diagnostics, drug delivery and therapeutic
Circulatory Biomarker Biology Program: AHERF has application.
established a wide array of circulatory biomarkers in
the form of cell free DNA, exosomes and circulatory Some of these are:
tumour cells. Exosomes form one of the major flagship
• Development of urinary biomarker for early renal
programs of CMBRC, AHERF. Exosome biology is
rejection
being now used to develop exosome-based

127